Suppr超能文献

纳米颗粒包裹的蛋白抗原高效诱导具有强大抗肿瘤活性的 T 细胞。

Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles.

机构信息

Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.

出版信息

Cancer Immunol Immunother. 2013 Jul;62(7):1161-73. doi: 10.1007/s00262-013-1411-0. Epub 2013 Apr 24.

Abstract

Protein antigen (Ag)-based immunotherapies have the advantage to induce T cells with a potentially broad repertoire of specificities. However, soluble protein Ag is generally poorly cross-presented in MHC class I molecules and not efficient in inducing robust cytotoxic CD8(+) T cell responses. In the present study, we have applied poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NP) which strongly improve protein Ag presentation by dendritic cells (DC) in the absence of additional Toll-like receptor ligands or targeting devices. Protein Ag-loaded DC were used as antigen presenting cells to stimulate T cells in vitro and subsequently analyzed in vivo for their anti-tumor effect via adoptive transfer, a treatment strategy widely studied in clinical trials as a therapy against various malignancies. In a direct comparison with soluble protein Ag, we show that DC presentation of protein encapsulated in plain PLGA-NP results in efficient activation of CD4(+) and CD8(+) T cells as reflected by high numbers of activated CD69(+) and CD25(+), interferon (IFN)-γ and interleukin (IL)-2-producing T cells. Adoptive transfer of PLGA-NP-activated CD8(+) T cells in tumor-bearing mice displayed good in vivo expansion capacity, potent Ag-specific cytotoxicity and IFN-γ cytokine production, resulting in curing mice with established tumors. We conclude that delivery of protein Ag through encapsulation in plain PLGA-NP is a very efficient and simple procedure to stimulate potent anti-tumor T cells.

摘要

基于蛋白质抗原 (Ag) 的免疫疗法具有诱导具有潜在广泛特异性的 T 细胞的优势。然而,可溶性蛋白质 Ag 通常在 MHC Ⅰ类分子中呈递较差,并且不能有效诱导强大的细胞毒性 CD8(+)T 细胞反应。在本研究中,我们应用了聚乳酸-羟基乙酸共聚物 (PLGA) 纳米颗粒 (NP),它在没有额外的 Toll 样受体配体或靶向装置的情况下,强烈改善了树突状细胞 (DC) 对蛋白质 Ag 的呈递。负载蛋白质的 DC 被用作抗原呈递细胞,在体外刺激 T 细胞,并随后通过过继转移进行体内分析,以评估其抗肿瘤作用。过继转移作为一种针对各种恶性肿瘤的治疗策略,已广泛在临床试验中进行研究。与可溶性蛋白质 Ag 直接比较,我们表明, plain PLGA-NP 包封的蛋白质的 DC 呈递导致 CD4(+)和 CD8(+)T 细胞的有效激活,这反映在激活的 CD69(+)和 CD25(+)、干扰素 (IFN)-γ 和白细胞介素 (IL)-2 产生的 T 细胞数量较高。在荷瘤小鼠中过继转移 PLGA-NP 激活的 CD8(+)T 细胞显示出良好的体内扩增能力、强大的 Ag 特异性细胞毒性和 IFN-γ 细胞因子产生能力,从而治愈了已建立肿瘤的小鼠。我们得出结论,通过封装在 plain PLGA-NP 中递送蛋白质 Ag 是刺激有效抗肿瘤 T 细胞的非常有效和简单的方法。

相似文献

8
CD69 does not affect the extent of T cell priming.CD69 并不影响 T 细胞的启动程度。
PLoS One. 2012;7(10):e48593. doi: 10.1371/journal.pone.0048593. Epub 2012 Oct 30.

引用本文的文献

9
Tumor progression and the different faces of the PERK kinase.肿瘤进展与PERK激酶的不同面貌
Oncogene. 2016 Mar 10;35(10):1207-15. doi: 10.1038/onc.2015.178. Epub 2015 Jun 1.

本文引用的文献

3
Cancer immunotherapy via dendritic cells.通过树突状细胞进行癌症免疫疗法。
Nat Rev Cancer. 2012 Mar 22;12(4):265-77. doi: 10.1038/nrc3258.
5
Decisions about dendritic cells: past, present, and future.关于树突状细胞的决策:过去、现在和未来。
Annu Rev Immunol. 2012;30:1-22. doi: 10.1146/annurev-immunol-100311-102839. Epub 2011 Nov 17.
10
MAGE-A family: attractive targets for cancer immunotherapy.MAGE-A 家族:癌症免疫治疗的有吸引力的靶标。
Vaccine. 2011 Nov 3;29(47):8496-500. doi: 10.1016/j.vaccine.2011.09.014. Epub 2011 Sep 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验